The macular cube 512 × 128 scan protocol was used to acquire all 128 OCT B-scans that covered an area of 6 × 6 mm and were 2 mm in length centered on the fovea. A mean retinal thickness (RT ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Feb. 6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic macular edema (DME) after studies showed that it could help maintain vision with as few as two ...

In this Healio Video Perspective from Hawaiian Eye 2025, Riad Sherif, MD, CEO of Oculis, discusses data on OCS-05 for the ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ...

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

The global diabetic macular edema market is on a steady growth trajectory ... citing good results from phase III trials on Vabysmo for retinal vein occlusion. Segmentation by drug includes anti-VEGF ...

and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema ...

The study will enroll patients with macular edema secondary to one of the following diseases: diabetic retinopathy ... KIO-104 works by suppressing T cell numbers and function in the eye ...